Skip to content
Wenlo
Sign in
← Markets

BridgeBio Pharma Inc.

Neil Kumar (Chief Executive Officer) sells BBIO shares

4BBIOFiled Sep 21, 2026, 2:21 PM ET· Period Sep 17, 2026

About this filing

BridgeBio Pharma Inc. (BBIO) filed Form 4 (insider transaction) with the SEC on Sep 21, 2026. Form 4 reports a company insider’s trades in the company’s shares.

View original filing on SEC.gov (opens SEC EDGAR)

Key facts

Insider
Neil Kumar · Chief Executive Officer, Director

Rule 10b5-1 plan · adopted May 13, 2026

DateTransactionSharesPriceValueHeld afterOwnership
Sep 17, 2026S · open-market saleFootnotes F1, F2, F3−8,721$69.01$601,867.61496,965Indirect (By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.)
Sep 17, 2026S · open-market saleFootnotes F1, F4, F3−1,279$69.57$88,979.52495,686Indirect (By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.)
Footnotes
  1. F1 This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026.
  2. F2 Represents the weighted average sale price of the shares sold from $68.52 to $69.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
  3. F3 The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
  4. F4 Represents the weighted average sale price of the shares sold from $69.525 to $69.64 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
  5. F5 These shares are held by the NK 2026 GRAT, a grantor retained annuity trust of which the Reporting Person is the sole trustee and sole annuitant. The Reporting Person disclaims beneficial ownership of the shares held by the NK 2026 GRAT except to the extent of his pecuniary interest therein.

More BBIO filings

Not investment advice. Summaries can contain errors; the SEC filing is the official record.